BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 30958637)

  • 1. Biologics exposure during pregnancy and breastfeeding in a psoriasis patient.
    Mugheddu C; Atzori L; Lappi A; Murgia S; Rongioletti F
    Dermatol Ther; 2019 May; 32(3):e12895. PubMed ID: 30958637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: A patient series.
    Lund T; Thomsen SF
    Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28071837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab.
    Galluzzo M; D'Adamio S; Bianchi L; Talamonti M
    J Dermatolog Treat; 2019 Feb; 30(1):40-44. PubMed ID: 29676599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry.
    Zweegers J; van den Reek JM; van de Kerkhof PC; Otero ME; Kuijpers AL; Koetsier MI; Arnold WP; Berends MA; Weppner-Parren L; Ossenkoppele PM; Njoo MD; Mommers JM; van Lümig PP; Driessen RJ; Kievit W; de Jong EM
    Br J Dermatol; 2016 Aug; 175(2):340-7. PubMed ID: 26989852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Case Series of Patients With Psoriasis Exposed to Biologic Therapy During Pregnancy: The BIOBADADERM Register and a Review of the Literature.
    Echeverría-García B; Nuño-González A; Dauden E; Vanaclocha F; Torrado R; Belinchón I; Pérez-Zafrilla B;
    Actas Dermosifiliogr; 2017 Mar; 108(2):168-170. PubMed ID: 27765165
    [No Abstract]   [Full Text] [Related]  

  • 6. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development.
    Matro R; Martin CF; Wolf D; Shah SA; Mahadevan U
    Gastroenterology; 2018 Sep; 155(3):696-704. PubMed ID: 29857090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Kimball AB; Guenther L; Kalia S; de Jong EMGJ; Lafferty KP; Chen DY; Langholff W; Shear NH
    JAMA Dermatol; 2021 Mar; 157(3):301-306. PubMed ID: 33533924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of moderate to severe plaque psoriasis in pregnancy and lactation in the era of biologics.
    Mervic L
    Acta Dermatovenerol Alp Pannonica Adriat; 2014; 23(2):27-31. PubMed ID: 24964946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ustekinumab exposure during conception and pregnancy in patients with chronic plaque psoriasis: a case series of 10 pregnancies.
    Watson N; Wu K; Farr P; Reynolds NJ; Hampton PJ
    Br J Dermatol; 2019 Jan; 180(1):195-196. PubMed ID: 30101563
    [No Abstract]   [Full Text] [Related]  

  • 10. Pregnancy during Ustekinumab Treatment for Severe Psoriasis.
    Rocha K; Piccinin MC; Kalache LF; Reichert-Faria A; Silva de Castro CC
    Dermatology; 2015; 231(2):103-4. PubMed ID: 25790947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic.
    Sorenson E; Koo J
    J Dermatolog Treat; 2015; 26(6):493-501. PubMed ID: 25886082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
    Papp KA; Gordon KB; Langley RG; Lebwohl MG; Gottlieb AB; Rastogi S; Pillai R; Israel RJ
    Br J Dermatol; 2018 Aug; 179(2):320-328. PubMed ID: 29488226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
    Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
    JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Routine Laboratory Parameter Dynamics and Laboratory Adverse Events in Psoriasis Patients on Long-term Treatment with Adalimumab, Etanercept, and Ustekinumab.
    Hoffmann JH; Knoop C; Enk AH; Hadaschik EN
    Acta Derm Venereol; 2017 Jun; 97(6):705-710. PubMed ID: 28224166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of a One-step Dose Reduction Strategy of Adalimumab, Etanercept and Ustekinumab in Patients with Psoriasis in Daily Practice.
    Atalay S; van der Schoot LS; Vandermaesen L; van Vugt LJ; Eilander M; van den Reek JMPA; de Jong EMGJ
    Acta Derm Venereol; 2021 May; 101(5):adv00463. PubMed ID: 33903920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence.
    Lin PT; Wang SH; Chi CC
    Sci Rep; 2018 Oct; 8(1):16068. PubMed ID: 30375427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient Preference for Dosing Frequency Based on Prior Biologic Experience.
    Zhang M; Carter C; Olson WH; Johnson MP; Brennem SK; Lee S; Farahi K
    J Drugs Dermatol; 2017 Mar; 16(3):220-226. PubMed ID: 28301617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Papp K; Gottlieb AB; Naldi L; Pariser D; Ho V; Goyal K; Fakharzadeh S; Chevrier M; Calabro S; Langholff W; Krueger G
    J Drugs Dermatol; 2015 Jul; 14(7):706-14. PubMed ID: 26151787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paradoxical ulcerative colitis during adalimumab treatment of psoriasis resolved by switch to ustekinumab.
    Kolios AGA; Biedermann L; Weber A; Navarini AA; Meier J; Cozzio A; French LE
    Br J Dermatol; 2018 Feb; 178(2):551-555. PubMed ID: 28477389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterizing patients with psoriasis on injectable biologics adalimumab, etanercept, and ustekinumab: A chart review study.
    Zhang M; Goren A; Lee S; DiBonaventura MD; Olson WH
    J Dermatolog Treat; 2016 Aug; 27(4):339-45. PubMed ID: 26558924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.